Industry News

MYnd Analytics, will present“ Disruptive Technology Gets Personal” on September 25, 2016 at the Annual Conference of the American College of Private Physicians.. The presentation will focus on the use of predictive analytics to guide medication selection."/>
Dr. Mark Schiller to present PEER at American College of Private Physicians
Enzo Biochem Assay Platform, Further Underscoring Growing Importance of Company's Clinically Relevant Diagnostics. NEW YORK, NY- Enzo Biochem, Inc. today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' PLAQPRO (TM) Lp-PLA2 Assay. This cardiac assay delivers improved consistency and is designed to work on open platform clinical analysis instruments."/>
Enzo Biochem Announces New York State Health Department Approval of New Easily Adaptable, Cost Effective Cardiac Assay
Agilent Technologies Inc. today announced that a quarterly dividend of 11.5 cents per share of common stock will be paid on Oct. 26, 2016, to all shareholders of record as of the close of business on Oct. 4, 2016.. The timing and amounts of future dividends are subject to determination and approval by Agilent's board. Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a..."/>
Agilent Technologies Announces Cash Dividend of 11.5 Cents per Share
Navamedic ASA, the Norwegian medtech and pharmaceutical products company, today announced it has commenced distribution of angina prevention medicine, Imdur ®, in the Nordic markets. The initiation of the distribution is the first step in the long-term strategic partnership with TopRidge Pharma Limited.. "We are pleased to announce that we now have commenced distribution of Imdur in the Nordic markets, seeing the long-term strategic partnership with..."/>
Navamedic: Commences distribution of Imdur® in Europe
CTI BioPharma Corp. today announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company's common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days prior to that date. CTI BioPharma Corp. is a biopharmaceutical company..."/>
CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule
Misonix, Inc.. Investors who purchased or otherwise acquired Misonix shares between November 5, 2015 and September 14, 2016 inclusive, are encouraged to contact the Firm prior to the November 18, 2016 lead plaintiff motion deadline.. If you purchased shares of Misonix during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA..."/>
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Misonix, Inc. and Encourages Investors with Losses to Contact the Firm
aTyr Pharma, Inc., today announced that David J. King, PhD, has joined the company as Senior Vice President, Research. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical development of meaningful medicines that target immune and tissue homeostatic pathways for patients with various severe and rare diseases. King is uniquely qualified to help us execute on our mission to bring..."/>
ATyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
Gilead Sciences, Inc. today announced that the company is stopping its combined Phase 2/ 3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active ulcerative colitis. This decision follows a planned interim analysis of unblinded efficacy and safety data by the Data Monitoring Committee after the first 150 patients of a planned 1600- patient trial were treated for an 8- week induction duration."/>
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Kadmon Holdings, Inc. today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase 2 clinical trial of KD025, the Company’ s oral inhibitor of Rho-associated coiled-coil kinase 2, in moderate to severe chronic plaque psoriasis. The dose-finding study examines KD025 administered at four doses: 200 mg once daily, 200 mg twice daily, 400 mg QD and 600 mg QD compared to matching placebo BID for 16 weeks in approximately 150 patients in the..."/>
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
Analogic Corporation, enabling the world's medical imaging and aviation security technology, today announced results for its fourth quarter and fiscal year ended July 31, 2016.. Highlights during the fourth quarter included:. Revenue of $138.1 million, down 11% Gross margin of 45.9%, up 4.4 pts. GAAP operating margin of 10.2%; Non-GAAP operating margin of 14.3%, up 40 bps. GAAP diluted EPS of $0.70; Non-GAAP diluted EPS of $1.02."/>
Analogic Announces Results for the Fourth Quarter and Fiscal Year Ended July 31, 2016 and Declares Quarterly Cash Dividend
Ocera Therapeutics, Inc., today announced completion of enrollment in STOP-ALF, a Phase 2 a clinical trial to evaluate the S afety and T olerability of O rnithine P henylacetate in patients with A cute L iver F ailure. The study was conducted by the Acute Liver Failure Study Group, an NIH-sponsored network of university tertiary care liver transplant sites, with support and supply of study medication from Ocera.."/>
Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
Agilent Technologies Inc. today announced that a quarterly dividend of 11.5 cents per share of common stock will be paid on Oct. 26, 2016, to all shareholders of record as of the close of business on Oct. 4, 2016.. The timing and amounts of future dividends are subject to determination and approval by Agilent’ s board. Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a..."/>
Agilent Technologies Announces Cash Dividend of 11.5 Cents Per Share
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of Thomas H. Adams, Ph.D., to the Company's Board of Directors. Adams is a seasoned biotechnology veteran who also currently serves as Chairman of the Board for Trovagene, Inc.. James Sapirstein, Chief Executive Officer of ContraVir, stated, "Tom is an accomplished..."/>
ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors
Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Leerink Partners Rare Disease Roundtable at 1:05 PM ET on September 28, in New York, NY. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com."/>
Sage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable
Kadmon Holdings, Inc. today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’ s rho-associated coiled-coil kinase 2 inhibitor, for the treatment of chronic graft-versus-host disease. The randomized, open-label, 24- week study examines the safety, tolerability and activity of KD025 dosed at 200 mg once daily, 200 mg twice daily or 400 mg QD in 48 cGVHD patients in the United States. cGVHD is a common and often fatal complication..."/>
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
Concert Pharmaceuticals, Inc. today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656 under fasted and fed conditions along with results from the Phase 1 multiple ascending dose study will be presented. Details on the upcoming poster presentation follow below."/>
Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology798 Articles
Consumer Discretionary691 Articles
Financials533 Articles
Health Care489 Articles
Industrials451 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.